About the Authors

Shaija Samuel

Affiliation Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America

Puja Gaur

Affiliation Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America

Fan Fan

Affiliation Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America

Ling Xia

Affiliation Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America

Michael J. Gray

Affiliation Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America

Nikolaos A. Dallas

Affiliation Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America

Debashish Bose

Affiliation Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America

Cristian Rodriguez-Aguayo

Affiliation Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America

Gabriel Lopez-Berestein

Affiliations Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, Center for RNA Interference and Non-Coding RNA, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America

Greg Plowman

Affiliation Tumor Biology and Angiogenesis, Genentech, Inc., South San Francisco, California, United States of America

Anil Bagri

Affiliation Tumor Biology and Angiogenesis, Genentech, Inc., South San Francisco, California, United States of America

Anil K. Sood

Affiliations Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, Center for RNA Interference and Non-Coding RNA, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America

Lee M. Ellis

lellis@mdanderson.org

Affiliations Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, Center for RNA Interference and Non-Coding RNA, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America

Competing Interests

LE is a consultant to Genentech, Inc., who provided the NRP-2 antibodies, and to Roche. GP and AB were paid employees of Genentech at the time of the study. A patent application has been filed relating to the anti-NRP antibodies from Genentech that were used in this manuscript. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Author Contributions

Conceived and designed the experiments: SS LE. Performed the experiments: SS PG FF LX MG ND DB. Analyzed the data: SS LE. Contributed reagents/materials/analysis tools: SS CR-A GL-B AS GP AB. Wrote the paper: SS LE.